Glucomannan
Also called: konjac glucomannan, konjac, konjac root fiber, konjac-mannan
Glucomannan is a soluble fiber from the tuber of the konjac plant (Amorphophallus konjac; Health Canada also lists A. bulbifer and A. muelleri). It can absorb up to 50 times its weight in water.
- Category
- Other
- Forms
- Glucomannan from Amorphophallus tuber, as oral capsules and powders (Health Canada's monograph excludes other forms); tablets have been linked to esophageal obstruction
- Strongest evidence
- A Strong
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2017 meta-analysis (Am J Clin Nutr) pooled 12 RCTs (370 participants; 8 in adults, 4 in children) of konjac glucomannan for LDL and non-HDL cholesterol. [4]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
AHeart and blood vessels1 topic
CBlood sugar and weight2 topics
CStomach and gut1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| LDL and non-HDL cholesterol | A | A 2017 meta-analysis of 12 RCTs (370 participants; 8 in adults, 4 in children) found LDL cholesterol fell 0.35 mmol/L and non-HDL 0.32 mmol/L; about 3 g/day lowered them by 10% and 7%. [4] |
| Body weight in overweight or obese people | C | Pooling 8 placebo-controlled RCTs showed no statistically significant weight loss (mean difference -0.22 kg); reporting quality varied across trials. [3] |
| Weight loss (NIH ODS summary) | C | ODS describes effects on weight as inconsistent: a 2015 review of 6 trials (293 participants, 1.24–3.99 g/day for up to 12 weeks) found no significant effect on body weight. [2] |
| Functional constipation in children | C | A meta-analysis of 3 RCTs (122 children) found more frequent bowel movements but no difference in stool consistency or treatment success; the authors urge caution given the small samples. [5] |
Main constituents: Glucomannan, described in 21 CFR 201.319 as (B-1,4 linked) polymannose acetate, a water-soluble gum [6]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- About 3 g/day of konjac glucomannan in the LDL cholesterol meta-analysis; included trials lasted 3 weeks or more. [4]
- Health Canada's glucomannan monograph (July 26, 2024), adults: 1–1.5 g three times per day for cholesterol lowering, taken 0.5–1 hour before meals; 0.5–5 g three times per day as a bulk-forming laxative; drink at least 250 mL of liquid with each dose. [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingHealth Canada's glucomannan monograph requires the label caution to ask a health care practitioner before use if pregnant or breastfeeding.
1 statement in the profile.
Details and sources - Interactions with medicines2 listed
Other medications and health products; Diabetes
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked. The profile notes other test results.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Health Canada NNHPD Glucomannan monograph (July 26, 2024), adults 18 years and older, capsules or powder only: 1–1.5 g of glucomannan 3 times per day …
Details and sources
- FDA (21 CFR 201.319): esophageal obstruction and asphyxiation have been associated with ingestion of water-soluble gums including glucomannan; these are significant risks when taken without adequate fluid or by people with esophageal narrowing or dysfunction or difficulty swallowing. [6]
- ODS: seven cases of esophageal obstruction were reported in Australia in 1984–1985 with glucomannan tablets; ODS advises caution with tablet forms and states powders and capsules have not been linked to this effect. [2]
- Health Canada: taking glucomannan with insufficient liquid may cause choking or blockage of the throat, esophagus or intestine; do not use if you have difficulty swallowing; seek care immediately for chest pain, vomiting, or difficulty swallowing or breathing after a dose. [1]
- FDA Import Alert 33-15: FDA warned in 2001 about choking caused by konjac (glucomannan) candy after several choking deaths and near-deaths among children and elderly people who ate mini-cup gel and jelly candies; an FDA board and CPSC physiologists concluded these pose a serious choking risk, particularly in young children. [7]
- ODS: long-term safety is poorly understood; short-term use appears well tolerated, with minor effects such as belching, bloating, loose stools, flatulence, diarrhea, constipation and abdominal discomfort. [2]
- Health Canada requires label cautions to ask a health care practitioner before use if pregnant or breastfeeding, or if you have diabetes or a lazy bowel; do not use with fever or undiagnosed gastrointestinal trouble. [1]
Interactions
| With | What happens |
|---|---|
| Other medications and health products | Health Canada directs taking glucomannan a few hours before or after other medications or health products. [1] |
| Diabetes | Health Canada requires a caution to ask a health care practitioner before use if you have diabetes. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Regulatory status
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [8]
- US: OTC drug products with glucomannan or another water-soluble gum as an active ingredient, sold in dry or incompletely hydrated form, are misbranded unless labeled with a "Choking" warning and directions (21 CFR 201.319). [6]
- US: Import Alert 33-15 allows detention without physical examination of mini-cup gel and jelly candies of firm consistency that present a choking risk. [7]
- US: no NDI notification naming glucomannan was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30). [9]
- Canada: Health Canada publishes a glucomannan monograph (July 26, 2024) for licensed natural health products for cholesterol lowering and as a bulk-forming laxative, limited to capsule and powder forms. [1]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Glucomannan ((B-1,4 linked) polymannose acetate), a water-soluble gum Polysaccharides [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming glucomannan was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
- 21 CFR 201.319: OTC drug products containing glucomannan or another water-soluble gum as an active ingredient in a dry or incompletely hydrated oral form are misbranded unless their labeling bears a "Choking" warning and directions, because esophageal obstruction and asphyxiation have been associated with these gums. [P1]
- FDA Import Alert 33-15 (published 08/04/2026; last revised 05/22/2025) covers mini-cup gel and jelly candies of firm consistency that present a choking risk; FDA warned in 2001 about choking caused by konjac candy after several choking deaths. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of glucomannan or konjac was found (IARC Monographs cumulative cross index, Volumes 1 to 142, and NTP technical reports index TR-001 to TR-606, checked 2026-10-30). [P4]
- The NTP Technical Reports index lists no 2-year study of glucomannan (checked 2026-10-30). [P5]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P7]
Supply and conservation
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Health Canada NNHPD Glucomannan monograph (July 26, 2024), adults 18 years and older, capsules or powder only: 1–1.5 g of glucomannan 3 times per day for cholesterol lowering (0.5–1 hour before meals; ask a practitioner for use beyond 8 weeks); 0.5–5 g 3 times per day as a bulk-forming laxative; drink at least 250 mL of liquid with each dose. [P6]
Pregnancy and breastfeeding
- Health Canada's glucomannan monograph requires the label caution to ask a health care practitioner before use if pregnant or breastfeeding. [P6]
Sources for this profile
- eCFR. 21 CFR 201.319, Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids as active ingredients; required warnings and directions (up to date as of 10/29/2026), 2026-10-29. ecfr.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. Import Alert 33-15: Detention Without Physical Examination of Mini-cup Gel and Jelly Candies of Firm Consistency that Present Risk of Choking (published 08/04/2026), 2026-08-04. accessdata.fda.gov
- IARC Monographs. Cumulative Cross Index to IARC Monographs Volumes 1 to 142 (PDF, retrieved 2026-10-30), 2026-10-30. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-30. ntp.niehs.nih.gov
- Health Canada NNHPD. Natural health product monograph: Glucomannan (date July 26, 2024), 2024-07-26. webprod.hc-sc.gc.ca
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/29/2026), 2026-10-29. ecfr.gov
- GBIF species API: IUCN Red List category for Amorphophallus konjac K.Koch, 2026-10-30. api.gbif.org
Sources
- Health Canada NNHPD. Natural health product monograph: Glucomannan (date July 26, 2024), 2024-07-26. webprod.hc-sc.gc.ca
- NIH Office of Dietary Supplements. Dietary Supplements for Weight Loss: Fact Sheet for Health Professionals (no printed update date captured; page last modified 2026-10-22 per page metadata), 2026-10-22. ods.od.nih.gov
- Onakpoya I, et al. The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. J Am Coll Nutr 2014;33(1):70-78 (PMID 24533610), 2014. pubmed.ncbi.nlm.nih.gov
- Ho HVT, et al. A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B. Am J Clin Nutr 2017;105(5):1239-1247 (PMID 28356275), 2017-05. pubmed.ncbi.nlm.nih.gov
- Han Y, et al. Effect of glucomannan on functional constipation in children: a systematic review and meta-analysis of randomised controlled trials. Asia Pac J Clin Nutr 2017;26(3):471-477 (PMID 28429913), 2017-05. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 201.319, Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids as active ingredients; required warnings and directions (up to date as of 10/29/2026), 2026-10-29. ecfr.gov
- FDA. Import Alert 33-15: Detention Without Physical Examination of Mini-cup Gel and Jelly Candies of Firm Consistency that Present Risk of Choking (published 08/04/2026), 2026-08-04. accessdata.fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (Content current as of 08/27/2026), 2026-08-27. fda.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.